TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02234934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentiviral G1XCGD Gene Therapy
Description: The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentiviral G1XCGD Gene Therapy
Description: The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell.
Study: NCT03233776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
Study: NCT04223648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
Description: Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy.
Study: NCT03486431

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
Study: NCT01124617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
Study: NCT01183884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Description: 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2.
Study: NCT00660387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa carbidopa intestinal gel (LCIG)
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) oral capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-tube
Description: jejunal tube
Study: NCT01457092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)
Description: Placement of self-expandable metal stents
Study: NCT04009876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of the tumour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch-and-wait
Description: No surgery approach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Study: NCT02213887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg PO QAM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0 mg PO QAM
Study: NCT04219527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-target injection
Description: Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)
Study: NCT04501536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word Learning Intervention
Description: The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word Learning Intervention
Description: The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
Study: NCT00856349

Intervention type: BEHAVIORAL
Intervention: Therapy Programming Report (TPR)
Description: Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
Study: NCT02914457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological Study
Description: Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
Study: NCT03419962

Intervention type: DRUG
Intervention: MaxSpiolto® Respimat® 160 Characters...
Description: as per the approved SmPC
Study: NCT01485718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucomannan
Description: Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
Study: NCT02754492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure
Study: NCT01937806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: besifovir 150mg
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir 300mg
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study: NCT04391517

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SpHb measurement
Description: All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
Study: NCT01579006

Intervention type: DRUG
Intervention: Tocilizumab
Study: NCT02026479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 5mg; postauricular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 10mg; postauricular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginaton
Description: 40mg/pill, 3times/day,oral
Study: NCT03645876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: 7.5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000mg/m2
Study: NCT02847585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-soluble Ubiquinol
Description: 10 mg/kg BW/d, by oral drops
Study: NCT02843022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized electronic messages
Description: supportive and educational short messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized electronic messages
Description: supportive and educational short messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse phone call if requested
Description: If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response
Study: NCT02759354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age
Study: NCT02843022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff nurse phone follow-up
Description: Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff nurse phone follow-up
Description: Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
Study: NCT02759354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age
Study: NCT03640767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based lifestyle intervention
Description: Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
Study: NCT00557401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 20 mg QD
Description: XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 40 mg QD
Description: XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 60 mg QD
Description: XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 30 mg BID
Description: XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally for approximately 32 days with titration and taper periods.
Study: NCT04447378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5Mg/0.5Ml Inj Syr
Description: post natal thromboprophylaxis
Study: NCT04704284

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
Description: Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
Study: NCT01437878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: 5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01194427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat and Tamoxifen
Description: vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
Study: NCT03453411

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study: NCT02843022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staff nurse phone follow-up
Description: Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
Study: NCT01488110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-house prototype invented by Jan-Erik Juto
Description: 30 minutes treatment with an active nasal probe.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: In-house prototype invented by Jan-Erik Juto
Description: 30 minutes treatment with an inactive nasal probe.
Study: NCT02381899

Intervention type: DRUG
Intervention: Bendamustine and Rituximab
Description: Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04138940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Training
Description: Participant uses a computer program to practice scripts with a virtual therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Training
Description: Participant uses a computer program to practice scripts with a virtual therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Training
Description: Participant uses a computer program to practice scripts with a virtual therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Training
Description: Participant uses a computer program to practice scripts with a virtual therapist.
Study: NCT04865562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone propionate
Description: 1mg/0.1mL solution, to be administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% cholorbutanol, saline
Description: 125 mg 0.5% cholorbutanol, 50mg saline
Study: NCT02135939

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Whole foods plant based vegan diet vs the American Heart Association-recommended diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Whole foods plant based vegan diet vs the American Heart Association-recommended diet
Study: NCT00832390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
Study: NCT01771575

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Placebo device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS™ device
Description: The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
Study: NCT04405427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: head acupoints acupuncture
Description: The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: body acupoints acupuncture
Description: The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
Study: NCT02313324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWD combined IFC
Description: The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
Study: NCT04664244

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of nimotuzumab and radiotherapy
Description: Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.